- Home
- SKYE vs EML Comparison
SKYE vs EML Comparison
Compare SKYE & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- EML
- Stock Information
- Founded
- SKYE 2012
- EML 1858
- Country
- SKYE United States
- EML United States
- Employees
- SKYE N/A
- EML N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- EML Industrial Machinery/Components
- Sector
- SKYE Health Care
- EML Consumer Discretionary
- Exchange
- SKYE Nasdaq
- EML Nasdaq
- Market Cap
- SKYE 94.0M
- EML 191.3M
- IPO Year
- SKYE N/A
- EML N/A
- Fundamental
- Price
- SKYE $2.73
- EML $26.66
- Analyst Decision
- SKYE Buy
- EML
- Analyst Count
- SKYE 6
- EML 0
- Target Price
- SKYE $18.67
- EML N/A
- AVG Volume (30 Days)
- SKYE 167.7K
- EML 11.4K
- Earning Date
- SKYE 02-09-2025
- EML 11-01-2024
- Dividend Yield
- SKYE N/A
- EML 1.66%
- EPS Growth
- SKYE N/A
- EML N/A
- EPS
- SKYE N/A
- EML N/A
- Revenue
- SKYE N/A
- EML $284,461,286.00
- Revenue This Year
- SKYE N/A
- EML N/A
- Revenue Next Year
- SKYE N/A
- EML N/A
- P/E Ratio
- SKYE N/A
- EML $13.23
- Revenue Growth
- SKYE N/A
- EML 7.70
- 52 Week Low
- SKYE $2.25
- EML $22.63
- 52 Week High
- SKYE $19.41
- EML $35.78
- Technical
- Relative Strength Index (RSI)
- SKYE 37.40
- EML 43.93
- Support Level
- SKYE $2.31
- EML $25.31
- Resistance Level
- SKYE $3.04
- EML $26.90
- Average True Range (ATR)
- SKYE 0.30
- EML 0.69
- MACD
- SKYE 0.07
- EML 0.00
- Stochastic Oscillator
- SKYE 44.68
- EML 54.66
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.